News for Healthier Living

Breakthrough Gene Therapy Shows Hope for Treating Fatal Childhood Leukodystrophy

Myrtelle Inc. ("Myrtelle"), a pioneering clinical-stage gene therapy company developing transformative treatments for neurodegenerative diseases, today announced the publication of interim results in Nature Medicine from a pioneering clinical study , reporting by researchers the first-in-human application of a gene therapy designed to restore myelin in the brains of children affected by Canavan Disease (CD), a rare and fatal pediatric leukodystrophy. The investigational treatment, known as MYR-101, uses a novel viral vector (rAAV-Olig001) with unique tropism for oligodendrocytes, the brain's myelin- producing cells.

September 16, 2025


September 16 2025

September 15 2025

September 14 2025

September 13 2025

September 12 2025

September 11 2025

September 10 2025

September 9 2025

September 8 2025

September 7 2025

September 6 2025

September 5 2025

September 4 2025

September 3 2025

September 2 2025